Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Teva's new asthma...

    Teva's new asthma inhaler poses first competition for GSK's Advair

    Written by Ruby Khatun Khatun Published On 2017-04-21T09:06:49+05:30  |  Updated On 21 April 2017 9:06 AM IST
    Tevas new asthma inhaler poses first competition for GSKs Advair
    By Divya Grover

    Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair.

    Teva, which won U.S. approval in January to make an inhaler similar to Advair, also launched a generic version of its own inhaler, AirDuo RespiClick.

    AirDuo is not a true generic of Advair, but contains the same two active ingredients, fluticasone propionate and salmeterol. However, it delivers a lower dose of salmeterol and uses Teva's RespiClick inhaler rather than copying GSK's device.

    "We imagine that there should be sufficient time window for AirDuo to be the sole competing product to Advair," Raymond James analyst Elliot Wilbur said in a client note.

    Advair, which brought in 1.83 billion pounds ($2.35 billion) in 2016 sales, is also widely used to treat chronic obstructive pulmonary disease, while AirDuo is only approved for asthma and is not directly substitutable.

    "Neither branded AirDuo, nor its authorized generic are therapeutically equivalent or substitutable for Advair," GSK's spokeswoman Sarah Alspach told Reuters.

    Still, Teva's product is likely to grab some share of the asthma market. AirDuo could capture 25 percent of the market by 2018, Wilbur said.

    However, the bigger threat to GSK will likely come from fully substitutable generic copies of Advair that are still awaiting approval.

    Hikma Pharmaceuticals Plc and Vectura Group Plc are expecting approval for their generic versions by May 10. Mylan NV's generic was rejected in March.

    GSK has been preparing for the loss of Advair's exclusivity for the past two years. But the potential launch of generics will still be a blow since the medicine is highly profitable and has sold more than $1 billion annually since 2001.

    Teva's AirDuo will cost wholesalers or direct purchasers $285, while the generic version will cost $90, Michelle Larkin, a spokeswoman for the Israeli drugmaker, told Reuters.

    The pricing of the branded drug was in line with that of its peers, Bernstein analyst Erica Kazlow said.

    "Teva's willingness to use generic strategy for the product is encouraging as it relates to the company's willingness to look at a tough reality and take appropriate action," Kazlow said.

    (Reporting by Divya Grover in Bengaluru; Editing by Saumyadeb Chakrabarty and Savio D'Souza)

    For more details click on the link given below.

    http://www.reuters.com/article/us-teva-pharm-ind-asthma-idUSKBN17M2K8
    AdvairAirDuo RespiClickasthma inhalerfluticasone propionateGSKsalmeterolSarah AlspachTeva Pharmaceutical
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok